tldrdaily.news logo
Tag

Adjuvant Therapy

All articles tagged with #adjuvant therapy

health1 year ago

"Why Some Cancer Patients, Like Kate Middleton, Need Both Chemotherapy and Surgery: An Oncologist's Perspective"

Oncologist Alexander Olawaiye explains that cancer treatment plans depend on the type and stage of cancer, with some patients receiving a combination of treatments such as surgery and chemotherapy. Factors like tumor aggressiveness, spread, and organ of origin influence the likelihood of recurrence. Adjuvant therapy, given after surgery, aims to kill any remaining cancer cells, while neoadjuvant therapy, given before surgery, can shrink tumors and reduce the extent of surgery required. These approaches, along with ongoing research, offer hope for more effective cancer treatment in the future.

via The Conversation Canada|
#adjuvant-therapy#cancer-treatment#chemotherapy
health1 year ago

"Understanding Kate Middleton's Preventive Chemotherapy and the Support She's Received"

Princess Kate is undergoing preventive chemotherapy after a recent diagnosis of cancer, following major abdominal surgery in January. This type of treatment, also known as adjuvant therapy, aims to eliminate microscopic cancer cells that may have been missed during initial treatment, reducing the risk of cancer recurrence. Preventive chemotherapy is not used for healthy individuals without a cancer diagnosis. Chemoprevention, on the other hand, involves using drugs or substances to lower the risk of developing cancer in the first place or prevent its recurrence, and is typically recommended for those at high risk due to family history or precancerous conditions.

via USA TODAY|
#adjuvant-therapy#cancer-treatment#chemoprevention
health1 year ago

"Royal Family Faces Cancer Crisis: Understanding Preventative Chemotherapy"

Princess Kate, the Princess of Wales, has announced that she is undergoing preventative chemotherapy following a cancer diagnosis. This form of early treatment aims to reduce the chance of cancer returning after surgery by targeting microscopic cancer cells that may remain in the body. The treatment, which can involve chemotherapy, radiation therapy, or hormone therapy, typically lasts for three months and may have side effects such as fatigue, nausea, and hair loss. The success of preventative chemotherapy depends on the type and stage of cancer, but early detection is seen as encouraging for the princess's recovery.

via CBS News|
#adjuvant-therapy#cancer#catherine-princess-of-wales
health2 years ago

KEYTRUDA® Shows Promising Results as Adjuvant Therapy for Renal Cell Carcinoma Patients

Merck's anti-PD-1 therapy, KEYTRUDA, has shown a statistically significant improvement in overall survival (OS) as adjuvant therapy for patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, according to the Phase 3 KEYNOTE-564 trial. This marks the first time a therapy has demonstrated a survival benefit compared to placebo in this patient population. The results build on the previously reported disease-free survival benefit from the same trial. KEYTRUDA's safety profile was consistent with previous studies, and the results will be presented at an upcoming medical meeting and submitted to regulatory authorities.

via Merck|
#adjuvant-therapy#clinical-trial#health
health2 years ago

Merck's KEYNOTE-671 Trial Shows Promising Overall Survival Results in Resectable NSCLC

Merck's Phase 3 KEYNOTE-671 trial investigating KEYTRUDA as a perioperative treatment for resectable stage II, IIIA, or IIIB non-small cell lung cancer (NSCLC) has met its dual primary endpoint of overall survival (OS). The trial demonstrated a statistically significant and clinically meaningful improvement in OS when KEYTRUDA was used as neoadjuvant therapy followed by surgery and adjuvant therapy, compared to placebo plus chemotherapy. These results mark a significant milestone in the treatment of resectable NSCLC and offer potential extended survival for patients in earlier stages of the disease.

via Merck|
#adjuvant-therapy#health#keytruda
health2 years ago

Merck's Keytruda Shows Promise in Muscle-Invasive Bladder Cancer Trial

Merck's anti-PD-1 therapy, KEYTRUDA, has met the primary endpoint of disease-free survival (DFS) in a Phase 3 clinical trial for the adjuvant treatment of patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced urothelial carcinoma. The trial demonstrated a statistically significant and clinically meaningful improvement in DFS compared to observation after surgery. The safety profile of KEYTRUDA was consistent with previous studies, and results will be presented at an upcoming medical meeting and discussed with regulatory authorities.

via Merck|
#adjuvant-therapy#clinical-trial#health